A comparison of six OCT devices

Article

In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study.

In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study.

The study, conducted by Dr Ute Wolf-Schnurrbusch and colleagues from the University of Bern, compared central retinal thickness (CRT) measurements in healthy eyes using different commercially available OCT devices and then compared the intersession reproducibility of the measurements. The instruments used were: the Stratus OCT (Carl Zeiss Meditec), SOCT Copernicus (Reichert/Optopol Technology), Spectral OCT/SLO (Opko/OTI), RTVue-100 (Optovue Corporation), Spectralis HRA+OCT and Cirrus HD-OCT (Carl Zeiss Meditec).

The study found that CRT measurements differed significantly between the various devices, with the Spectralis and Cirrus HD-OCT demonstrating higher values than all other instruments. The Spectralis was the only device with a coefficient of variation below 1.0 and the only instrument with a Smallest Measurable Change of less than 2 microns.

“The high repeatability of the Spectralis HRA+OCT measurements is most likely related to the unique feature of the system that allows eye tracking during the scanning process and automatic recognition of the exact same scan location for follow-up examination,” commented Dr Wolf-Schnurrbusch in a Heidelberg press release. “By using this feature for all follow-up scans with the Spectralis HRA+OCT we could minimise extrinsic factors, such as patient fixation and the operator’s ability to consistently place the macular grid over the same points during each scan.”

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.